Cancer Res Treat.  2016 Jan;48(1):71-79. 10.4143/crt.2015.018.

The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy

• Shim HJ
• Shin MH
• Kim HN
• Kim JH
• Hwang JE
• Bae WK
• Chung IJ
• Cho SH

• KMID: 2152262
• DOI: http://doi.org/10.4143/crt.2015.018

Abstract

PURPOSE
The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT).
MATERIALS AND METHODS
Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were assessed for the role of FGFR4 genotype on treatment response and survival.
RESULTS
A total of 94 patients were homozygous for the Gly388 allele, and 110 were heterozygous and 40 homozygous for the Arg388 allele. No significant association was found between the FGFR4 genotype and clinicopathological parameters. However, patients carrying the Gly388 allele showed a better overall response rate than Arg388 carriers (p=0.038). In addition, Gly388 allele patients at an earlier stage showed better overall survival (OS) and progression-free survival than Arg388 carriers. Among these, the Gly388 allele showed significantly improved OS compared to Arg388 carriers in the lymph node (LN) metastasis group (p=0.042) compared to the no LN metastasis group (p=0.125). However, similar survival outcomes were observed for advanced-stage disease regardless of genotype.
CONCLUSION
This result suggests that the role of FGFR4 Gly388 in treatment outcomes differs according to esophageal cancer stage. It showed a predictive role in the response of esophageal cancer patients to CRT with a better trend for OS in Gly388 than Arg388 carriers in the early stages. In particular, LN-positive early-stage patients carrying the Gly388 allele showed improved OS compared to those carrying Arg388.

Keyword

Biological markers; Chemoradiotherapy; Esophageal neoplasms; Fibroblast growth factor receptor 4

MeSH Terms

Alleles
Biological Markers
Carcinoma, Squamous Cell*
Chemoradiotherapy*
Disease-Free Survival
Esophageal Neoplasms
Genotype
Humans
Lymph Nodes
Neoplasm Metastasis
Receptor, Fibroblast Growth Factor, Type 4
Biological Markers
Receptor, Fibroblast Growth Factor, Type 4

Figure

• 

  Fig. 1. Association between genotype and survival outcome. In early stage of esophageal cancer, FGFR4 Gly388 allele (G/G) patients show better trends of progression-free survival (A) and overall survival (C) than FGFR4 Arg388 carriers (G/A or A/A) without statistical significance. However, the progression-free survival (B) and overall survival (D) in advanced stage of esophageal cancer patients show comparable outcomes regardless of genotypes.

• 

  Fig. 2. Survival according to genotype in early esophageal cancer. In early esophageal cancer, FGFR4 Gly388 allele patients showed a better trend of progression-free survival (A) (p=0.079) and significantly better overall survival (C) (p=0.042) than FGFR4 Arg388 carriers in lymph node (LN)-positive patients. However, there was no difference in LN-negative patients according to genotypes (B, D).

Reference

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10–29.

2. Kim DE, Kim UJ, Choi WY, Kim MY, Kim SH, Kim MJ, et al. Clinical prognostic factors for locally advanced esophageal squamous carcinoma treated after definitive chemoradiotherapy. Cancer Res Treat. 2013; 45:276–84.

3. Shim HJ, Kim DE, Hwang JE, Bae WK, Nam TK, Na KJ, et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol. 2012; 70:683–90.

4. Kelsey CR, Chino JP, Willett CG, Clough RW, Hurwitz HI, Morse MA, et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys. 2007; 69:770–6.

5. Hong TS, Wo JY, Kwak EL. Targeted therapies with chemoradiation in esophageal cancer: development and future directions. Semin Radiat Oncol. 2013; 23:31–7.

6. Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol. 2013; 85:1033–41.

7. Yang F, Zhang Y, Ressler SJ, Ittmann MM, Ayala GE, Dang TD, et al. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013; 73:3716–24.

8. Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan BC, Kennedy CW, O'Toole SA, et al. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer. 2013; 81:462–7.

9. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S, et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer. 2008; 123:2574–9.

10. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005; 23:7307–11.

11. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006; 24:3747–55.

12. Ansell A, Farnebo L, Grenman R, Roberg K, Thunell LK. Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol. 2009; 45:23–9.

13. Dutra RL, de Carvalho MB, Dos Santos M, Mercante AM, Gazito D, de Cicco R, et al. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx. PLoS One. 2012; 7:e50747.

14. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437:199–213.

15. Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med. 2011; 17:283–92.

16. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014; 34:280–300.

17. Taylor JG 6th, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009; 119:3395–407.

18. Ye Y, Shi Y, Zhou Y, Du C, Wang C, Zhan H, et al. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol. 2010; 17:3354–61.

19. Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, et al. FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res. 2013; 73:5926–35.

20. Pelaez-Garcia A, Barderas R, Torres S, Hernandez-Varas P, Teixido J, Bonilla F, et al. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer. PLoS One. 2013; 8:e63695.

21. Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stattner S, et al. Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res. 2012; 72:5767–77.

22. Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, et al. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 2006; 7:67–88.

23. Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, et al. FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. Proc Natl Acad Sci U S A. 2010; 107:15786–91.

24. Ye YW, Hu S, Shi YQ, Zhang XF, Zhou Y, Zhao CL, et al. Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer. Oncol Rep. 2013; 30:2777–84.